Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Obesity is a growing concern in India, contributing to conditions such as type-2 diabetes and cardiovascular ... BT: Are there other drugs in Eli Lilly’s pipeline targeting obesity or related ...

And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity. Even with Eli Lilly's Mounjaro and ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Global pharmaceutical company Eli Lilly's (LLY) preliminary 2024 revenue missed expectations on lower-than-expected sales of its weight loss and diabetes ... position in the pipeline for its ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...

Eli Lilly and Company (NYSE ... in approvals for new indications or pipeline products could impact revenue projections. 3. Payer Dynamics: Changes in insurance coverage or reimbursement policies for ...